| N-(4-Methoxyphenyl)-N-methylformamide (3a). 1H-NMR (CDCl3): δ 8.35 (s, 1H), 7.11 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 3.83 (s, 3H), 3.28 (s, 3H); EI-MS m/z 165 (M+), 153, 136, 122, 108, 94, 77, 65, 52. |
| N-(4-Methoxyphenyl)benzamide (3b). 1H-NMR (CDCl3): δ 7.87 (d, J = 7.2 Hz, 1H ), 7.79 (s, 1H), 7.56–7.46 (m, 5H), 6.91 (d, J = 9.3 Hz, 2H), 3.82(s, 3H); EI-MS m/z 227 (M+), 210, 178, 149, 122, 105, 77, 51. |
| N-(3-Aminophenyl)benzamide (3c). 1H-NMR (CDCl3): δ 7.85 (d, J = 7.2 Hz, 2H), 7.79 (s, 1H), 7.57–7.45 (m, 3H), 7.33 (s, 1H), 7.13 ( t, J = 7.8 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 6.48 (d, J1 = 8.1 Hz, J2 = 1.8 Hz,1H), 3.71 (s, 2H); EI-MS m/z 212 (M+), 184, 167, 135, 121, 105, 77, 51. |
| N-(3-(Trifluoromethyl)phenyl)benzamide (3d). 1H-NMR (CDCl3): δ 8.00–7.85 (m, 5H), 7.57–7.39 (m, 5H); EI-MS m/z 265 (M+), 246, 225, 149, 113, 105, 77, 51. |
| N-(4-Chlorophenyl)nicotinamide (3e). 1H-NMR (CDCl3): δ 9.08 (s, 1H), 8.78 (dd, J1 = 4.8 Hz, J2 = 1.5 Hz, 1H), 8.21 (d, J = 7.8 Hz, 1H), 8.04 (s, 1H), 7.62 (d, J = 9.0 Hz, 2H), 7.48–7.44 (m, 1H), 7.36 (d, J = 8.7 Hz, 2H); EI-MS m/z 232 (M+), 127, 106, 78, 51. |
| N-(4-Methoxyphenyl)cinnamamide (3f). 1H-NMR (CDCl3): δ 7.75 (d, J = 15.6 Hz, 1H), 7.54 (m, 4H), 7.38 (m, 3H), 6.90 (d, J = 8.7 Hz, 2H), 6.53 (d, J = 15.3 Hz, 1H), 3.81 (s, 3H); EI-MS m/z 253 (M+), 131, 123, 108, 103, 77, 51. |
| 1-(4-Methoxyphenyl)pyrrolidin-2-one (3g). 1H-NMR (CDCl3): δ 7.50 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz, 2H), 3.86–3.00 (m, 5H), 2.60 (t, J = 8.1 Hz, 2H), 2.16 (m, 2H); EI-MS m/z 191 (M+), 176, 166, 136, 121, 69, 57. |
| 1-(4-Acetylphenyl)pyrrolidin-2-one (3h). 1H-NMR (CDCl3): δ 7.98 (d, J = 8.7 Hz, 2H), 7.76 (d, J = 9.0 Hz, 2H), 3.91 (t, J = 7.2 Hz, 2H), 2.65 (t, J = 7.5 Hz, 2H), 2.59 (s, 3H), 2.20 (m, 2H); EI-MS m/z 203 (M+), 188, 160, 148, 132, 120, 105, 90, 77, 69, 63, 51, 43. |
| 1-(4-(Trifluoromethyl)phenyl)pyrrolidin-2-one (3i). 1H-NMR (CDCl3): δ 7.77 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H), 3.89 (t, J = 7.2 Hz, 2H), 2.64 (t, J = 7.8 Hz, 2H), 2.21 (m, 2H); EI-MS m/z 229 (M+), 210, 174, 145, 127, 95, 84, 57. |
| 1-o-Tolylpyrrolidin-2-one (3j). 1H-NMR (CDCl3): δ 7.27–7.21 (m, 3H), 7.16–7.13 (m, 1H), 3.72 (t, J = 7.2 Hz, 2H), 2.59 (t, J = 8.1 Hz, 2H), 2.28–2.18 (m, 5H), EI-MS m/z 175 (M+), 158, 146, 130, 120, 91, 65, 51. |
| 1-(3-(Trifluoromethyl)phenyl)piperidin-2-one (3k). 1H-NMR (CDCl3): δ 7.53–7.48 (m, 4H), 3.69–3.66 (m, 2H), 2.60–2.56 (m, 2H), 1.98–1.96 (m, 4H); EI-MS m/z 243 (M+), 224, 214, 187, 174, 149, 145, 120, 108, 91, 70, 55. |
| N-Methyl-N-(thiophen-3-yl)formamide (3l). 1H-NMR (CDCl3): δ 8.52 (s, 1H), 8.23 (s, 0.2H), 7.44–7.42 (m, 0.2H), 7.35–7.30 (m, 1.2 H), 7.25–7.23 (m, 0.2H), 6.99–6.97 (m, 1H), 6.84–6.83 (m, 1H), 3.30 (s, 0.6 H), 3.22 (s, 3H); EI-MS m/z 141 (M+), 112, 98, 85, 80, 72, 68, 58, 54, 45, 42. |
| N-(4-Fluorophenyl)-N-methylformamide (3m). 1H-NMR (CDCl3): δ 8.40 (s, 1H), 7.18–7.12 (m, 4H), 3.31 (s, 3H); EI-MS m/z 153 (M+), 124, 112, 95, 83, 77, 75, 57. |
| N-(4-Methoxyphenyl)-N-phenylformamide
(3n). 1H-NMR (CDCl3): δ 8.62 (d, J = 30.9 Hz, 1H), 7.38–7.34 (m, 2H), 7.31–7.19 (m, 3H), 7.16–7.11 (m, 2H), 6.92 (d, J = 9.0 Hz, 2H), 3.81 (d, J = 4.2 Hz, 3H); EI-MS m/z 227 (M+), 199, 184, 167, 154, 129, 124, 121, 103, 93, 77, 66, 51, 43 |
| N-Phenyl-N-m-tolylformamide (3o). 1H-NMR (CDCl3): δ 8.66 (d, J = 6.3 Hz,1H), 7.43–7.38 (m, 2H), 7.33–7.26 (m, 3H), 7.18–7.05 (m, 3H), 6.98 (s, 1H), 2.36–2.35 (d, J = 3.6 Hz, 3H); EI-MS m/z 211 (M+), 183, 167, 141, 128, 118, 108, 91, 80, 65, 51; EI-HRMS for C15H13NO2 (M+) requires 211.0997, found 211.0992. |
| N-(4-Acetylphenyl)-N-phenylformamide (3p). 1H-NMR (CDCl3): δ 7.86 (d, J = 8.1 Hz, 2H), 7.34 (t, J = 7.5 Hz, 2H), 7.18 (d, J = 7.5 Hz, 2H), 7.08 (t, J = 7.2 Hz, 1H), 6.99 (d, J = 8.4 Hz, 2H), 6.26 (s, 1H), 2.63 (s, 3H); 13C-NMR (CDCl3): δ 196.3, 148.2, 140.4, 130.5 (2C), 129.4 (2C), 128.9, 123.2, 120.5 (2C), 114.2 (2C), 97.6, 26.0; EI-MS m/z 239 (M+), 211, 196, 167, 139, 115, 98, 84, 77, 63, 51, 43; EI-HRMS for C15H13NO2 (M+) requires 239.0946, found 239.0944. |
| N-Benzyl-N-p-tolylformamide (3q). 1H-NMR (CDCl3): δ 8.50 (s, 1H), 7.28–7.21 (m, 5H), 7.13 (d, J = 8.1 Hz, 2H), 6.98 (d, J = 8.4 Hz, 2H), 4.97 (s, 2H), 2.32 (s, 3H); EI-MS m/z 225 (M+), 196, 181, 165, 133, 118, 91, 77, 65, 51 |
| N-Benzyl-N-(pyridin-2-yl)formamide (3r). 1H-NMR (CDCl3): δ 9.50 (s, 1H), 8.39 (d, J = 5.1 Hz, 1H), 7.62 (t, J = 7.2 Hz, 1H), 7.29–7.22 (m, 5H), 7.08 (m, 1H), 6.93(d, J = 8.1 Hz, 1H), 5.18 (s, 2H); EI-MS m/z 212 (M+), 183, 168, 154, 106, 91, 78, 65, 51 |
| N-Phenyl-N-(thiophen-3-yl)acetamide (3s). 1H-NMR (CDCl3): δ 7.46–7.18 (m, 7H), 7.18 (6.95, J = 5.7 Hz, 1H), 1.99 (s, 3H); EI-MS m/z 217 (M+), 175, 149, 130, 120, 104, 84, 77, 51, 43. |
| N-(4-Fluorophenyl)-N-phenylacetamide (3t). 1H-NMR (CDCl3): δ 7.32~7.15 (m, 9H), 2.33 (s, 3H), 2.05 (s, 3H). |
| N-(4-Fluorophenyl)-N-phenylacetamide (3u). 1H-NMR (CDCl3): δ 7.40~6.99 (m, 9H), 2.06 (s, 3H). |
| N-methyl-N-phenylacetamide (3v). 1H-NMR (CDCl3): δ 7.43 (t, J = 7.2 Hz, 2H), 7.34 (t, J = 7.2 Hz, 1H), 7.19 (d, J = 4.8 Hz, 2H), 3.27 (s, 3H), 1.87 (s, 3H); EI-MS m/z 149 (M+), 129, 120, 109, 106, 92, 81, 77, 65, 51, 43. |
| N-Cyclohexyl-N-phenylformamide (3w). 1H-NMR (CDCl3): δ 8.42 (s, 0.15H), 8.15 (s, 0.85H), 7.44–7.35 (m, 3H), 7.17–7.13 (m, 2H), 4.44–4.37 (m, 0.85H), 3.65–3.57 (m, 0.15H), 1.92–1.74 (m, 4H), 1.63–1.58 (m, 1H), 1.46–1.23 (m,4H), 1.05–0.95 (m, 1H); EI-MS m/z 203 (M+), 174, 160, 146, 132, 121, 118, 104, 93, 77, 66, 55, 51, 41. |